Showing 401-410 of 1954 results for "".
Topical Treatment Considerations for Psoriasis
https://practicaldermatology.com/topics/psoriasis/topical-treatment-considerations-for-psoriasis/18845/Jerry Bagel, MD and Neil J. Korman, MD discuss topical treatment options for treating patients with mild psoriasis. They share insights about the effect of vehicles on compliance, particularly when treating patients with scalp psoriasis.Clinical Conversations: How JAK Inhibitors are Changing the AD Treatment Landscape
https://practicaldermatology.com/series/jak-inhibitors-in-practice/clinical-conversations-how-jak-inhibitors-are-changing-the-ad-treatment-landscape/20092/With the approval of JAK inhibitors to treat eczema, the treatment landscape is changing. Matt Zirwas, MD and Adelaide Hebert, MD talk about the role for JAK inhibitors and key considerations for discussing options with patients.Effective Patient Consultations: Keys to Success
https://practicaldermatology.com/topics/practice-management/effective-patient-consultations-keys-to-success/20122/So much depends on the patient consultation, and its key that all members of the practice staff are attentive to the needs of the patient and the practice. Amy Lewis, MD and Mark Rubin, MD weigh in on strategies for effective patient interactions.Update on Keloids and Scarring
https://practicaldermatology.com/topics/general-topics/update-on-keloids-and-scarring/19267/Brian Berman, MD talks with host Joshua Zeichner, MD about the use of interferon and topical immune modulators for the management of keloids. What does the evidence show? What are optimal protocols?Active Vitiligo: What to Look For
https://practicaldermatology.com/series/updates-vitiligo/active-vitiligo-what-to-look-for/24156/John E. Harris, MD, founding director of the Autoimmune Therapeutics Institute at the University of Massachusetts Chan Medical School, talks with Practical Dermatology Chief Medical Editor Neal Bhatia, MD, about the clinical signs of active vitiligo.DermWireTV Extra: Dr. Bhatia and Dr. Schlesinger Discuss Collaboration With Oncologists
https://practicaldermatology.com/topics/skin-cancer-photoprotection/dr-bhatia-and-dr-schlesinger-discuss-collaboration-oncologists/26304/Practical Dermatology Chief Medical Editor Neal Bhatia, MD, and Editorial Board member Todd Schlesinger, MD, discuss the importance of collaborating with oncologists on advanced skin cancer cases as immunotherapy technology continues to progress.Journal Club: Height Improvement After Treatment
https://practicaldermatology.com/programs/Practical-Dermatology-Atopic-Dermatitis-Journal-Club/journal-club-height-improvement-after-treatment/32406/Practical Dermatology Editorial Board member Peter Lio, MD, talks with Amy Paller, MD, about research into patients with severe atopic dermatitis and lower stature achieving significant improvement in height following treatment with dupilumab.Pigmentation: Melasma vs. Postinflammatory Hyperpigmentation
https://practicaldermatology.com/conferences/maui-derm-2024/pigmentation-melasma-vs-hyperpigmentation-vitiligo-treatments-and-full-spectrum-photo-protection/20247/Chief Medical Editor Neal Bhatia, MD and Pearl Grimes, MD, discuss Dr. Grimes’ presentations on pigmentation, including the difference between melasma and postinflammatory hyperpigmentation, and the importance of photo-protection in darker skin types.Exciting Developments in Treating Pediatric Dermatology
https://practicaldermatology.com/conferences/maui-derm-2024/exciting-developments-in-treating-pediatric-dermatology/20246/Chief Medical Editor Neal Bhatia, MD and Lawrence Eichenfield, MD, discuss the range of therapies currently approved or in the pipeline for atopic dermatitis, pruritus, pediatric acne--and the importance of messaging on TikTok.“No Drug is 100 Percent.”
https://practicaldermatology.com/conferences/maui-derm-2024/no-drug-is-100-percent/20242/Jason Hawkes, MD and Chief Medical Editor Neal Bhatia, MD discuss how the current array of options for patients of chronic spontaneous urticaria (CSU) expand treatment options for hives beyond antihistamines.